Search results for "osteonecrosi"

showing 10 items of 207 documents

The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists

2022

Abstract Purpose The prevention and early diagnosis of medication-related osteonecrosis of the jaw (MRONJ) is fundamental to reducing the incidence and progression of MRONJ. Many in the field believe that dental hygienists should play an integral role in primary and secondary MRONJ prevention. However, to date, very few publications in the literature have proposed standardised MRONJ protocols, which are dedicated to dental hygienists. The aim of this study was to provide guidance to the health care providers managing MRONJ. Methods The expert opinion in this study was developed by dental hygienists from the main Italian technical-scientific associations (Italian Dental Hygienists Associatio…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawRisk factorsOncologyDental hygienistsIncidencePreventionHumansDental hygienists; MRONJ; Osteonecrosis of the jaw; Periodontal screening score; Prevention; Risk factorsBisphosphonate-Associated Osteonecrosis of the JawPeriodontal screening scoreMRONJSupportive Care in Cancer
researchProduct

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication

2021

The purpose of this study was to compare jaw and cervical vertebrae bone density in computed tomography (CT) analyses of oncological patients undergoing antiresorptive medication with control patients, aiming to find information that may assist the radiologist and clinician in predicting risks and monitoring osteonecrosis in the jaw. Thirty-one patients treated with zoledronic acid and 37 control were included in the study. Two areas in regions of interest were chosen and standardized, one in the lower portion of the mandible and another in the axial cervical vertebra (C2) of patients undergoing antiresorptive drug treatment (experimental group) and the control group. Density analysis was p…

Bone Density Conservation AgentsDiphosphonatesReproducibility of Resultsmyofibromadesmoplastic fibromaOtorhinolaryngologynodular fasciitisBone DensityHumansmyofibroblastic sarcomaBisphosphonate-Associated Osteonecrosis of the JawSurgeryinflammatory myofibroblastic tumorTomography X-Ray ComputedGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

2023

Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ. Methods This multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients’ data were retrospectively collected from the clinical charts of seven recruiting Italian centres. Results MRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandi…

Bone modifying agentsBreast cancerOsteonecrosis of the jawCancer treatment-induced bone lossONJCTIBLMRONJGeneral DentistryBone modifying agents; Breast cancer; CTIBL; Cancer treatment-induced bone loss; MRONJ; ONJ; Osteonecrosis of the jawBMC Oral Health
researchProduct

Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.

2010

Bisphosphonate associated osteonecrosis of the jaw (BP-ONJ) is one of the main side effects of bisphosphonate therapy (BPT). To date, there is no effective therapy of the BP-ONJ. Nitrogen-containing bisphosphonates (N-BPs) are particularly able to inhibit pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP). Consequent of decreased synthesis of the metabolite Geranylgeraniol (GGOH) is believed to largely account for the development of BP-ONJ. Negative effect of N-BPs could be shown, resulting in decreased viability and migration capacity of different cell types of hard and soft tissues such as osteoblasts, fibroblast und endothelial cells. Aim of our in vitro study was to demonstra…

Cancer Researchmedicine.medical_specialtyCell typeCellIn Vitro Techniqueschemistry.chemical_compoundGeranylgeraniolmedicineHumansFibroblastBisphosphonate-associated osteonecrosis of the jawMigration AssayOsteoblastsBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisEndothelial CellsFibroblastsmedicine.diseaseSurgerymedicine.anatomical_structureOncologychemistryCancer researchMevalonate pathwayOral SurgeryDiterpenesbusinessWound healingJaw DiseasesOral oncology
researchProduct

2014

ABSTRACT: Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors. Bone necrosis is almost irreversible and there is no definitive cure for ONJ with the exclusion, in certain cases,…

Cancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)CancerGeneral Medicinemedicine.diseaseSurgeryDenosumabOncologyInternal medicineAntiresorptive AgentsEpidemiologymedicinebusinessOsteonecrosis of the jawMultiple myelomaReduction (orthopedic surgery)medicine.drugFuture Oncology
researchProduct

A fatal iatrogenic right vertebral injury after transoral odontoidectomy and posterior cervical stabilization for a type II odontoid fracture.

2014

Abstract The authors present a singular case of an iatrogenic right vertebral artery injury, involving a 67 year-old man, who reported a type II odontoid fracture (Anderson and D'Alonzo Classification) and posterior atlantoaxial dislocation following a road traffic accident. A small injury involving the right vertebral artery occurred as a consequence of transoral odontoidectomy and posterior cervical stabilization. It was caused by bone spicules of spinal origin and their presence was confirmed by the histological section of the right vertebral artery at the level of C1–C2. The case confirms how iatrogenic vertebral artery injuries during cervical spine surgery may be potentially lethal, e…

Cervical spine surgeryMalemedicine.medical_specialtyVertebral arteryIatrogenic DiseaseJoint DislocationsArterial Occlusive DiseasesOdontoid fracturePathology and Forensic MedicineFatal OutcomeSettore MED/43 - Medicina Legalemedicine.arteryOdontoid ProcessingleseRight vertebral arteryMedicineHumansSingular caseVertebral ArteryOdontoid fractureAgedbusiness.industryAtlantoaxial dislocationTransoral odontoidectomyAccidents TrafficOsteonecrosisVertebral injuryThrombosisGeneral MedicineDecompression SurgicalSurgeryRoad traffic accidentAtlanto-Axial JointVertebral artery injuryCerebrovascular CirculationHypoxia-Ischemia BrainCervical VertebraeSpinal FracturesRadiologybusinessLawJournal of forensic and legal medicine
researchProduct

Use of bone scintigraphy in the early diagnosis of bisphosphonate related osteonecrosis of the jaw. Case report and review of the literature

2018

The main aim of the present report is to show the potential utility of bone scintigraphy for the diagnosis of jaw osteonecrosis. We report the history of a 62-year-old woman underwent breast cancer surgery in 2010. Moreover, patient received postoperative radiotherapy and chemotherapy. Intravenous bisphosphonates were also added to the treatment strategy to reduce the risk of bone metastasis. However, a hypermetabolic focus on left hemimandible was evidenced with a bone scintigraphy during follow up. After a careful study, the diagnosis of Bisphosphonate Related Ostneonecrosis of the Jaw (BRONJ) was carried out. This case highlights that bone scintigraphy may be extremely helpful for the ea…

Chemotherapymedicine.medical_specialtyOral Medicine and Pathologymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPostoperative radiotherapyEarly detectionBone metastasisCase Report030206 dentistryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.disease03 medical and health sciences0302 clinical medicineBreast cancerBone scintigraphy030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASmedicineRadiologybusinessOsteonecrosis of the jawGeneral Dentistry
researchProduct

Comment on “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini in the Section “Simply Put: JOMS Information for Patients”

2021

We read with great interest the contribute to the section “Simply Put: JOMS Information for Patients” named “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini.

Comment medication-related osteonecrosis of the jaw mronj
researchProduct

Conservative surgical treatment of medication-related osteonecrosis of the jaws with Leukocyte-Platelet Rich Fibrin: preliminary results at nine mont…

2019

Conservative surgical treatment medication-related osteonecrosis of the jaws Leukocyte-Platelet Rich Fibrin
researchProduct